DEFM14A: Hologic, Inc. Stockholders to Vote on $17.9B Blackstone/TPG Merger

Hologic, Inc. stockholders are invited to a special meeting on February 5, 2026, to vote on a merger agreement with affiliates of Blackstone and TPG, offering $76.00 cash plus a CVR up to $3.00 per share.

Summary

• Hologic, Inc. (HOLX) entered into a merger agreement on October 21, 2025, with Hopper Parent Inc. and Hopper Merger Sub Inc., affiliates of Blackstone Inc. and TPG Global, LLC.
• The merger consideration is $76.00 per share in cash, plus one Contingent Value Right (CVR) representing the right to receive up to an additional $3.00 in cash, contingent on achieving specific Breast Health revenue thresholds in fiscal years 2026 and 2027.
• The Board of Directors unanimously determined the merger terms are fair and in the best interests of the Company and its stockholders, recommending a vote FOR the merger agreement, an advisory compensation proposal, and an adjournment proposal.
• A special meeting of stockholders will be held virtually on February 5, 2026, at 12:00 p.m. Eastern Time, for stockholders of record as of December 22, 2025.
• The total funds needed for the merger and related transactions are approximately $17.9 billion, funded by equity and debt financing from Blackstone and TPG affiliates.
• The merger is subject to stockholder approval, regulatory approvals (HSR Act, CFIUS, other antitrust laws), and no prohibitive laws or orders.
• The HSR Act waiting period was terminated early on December 17, 2025.
• The go-shop period ended on December 5, 2025, with no alternative acquisition proposals received.

Sentiment

Score: 8

Explanation: The Board unanimously recommends the merger, which offers a substantial premium over the unaffected share price, providing immediate cash value and potential upside through the CVR. While there are risks associated with the CVR's contingent nature and operational restrictions, the overall tone is positive regarding the value proposition for shareholders.

Positives

• The merger consideration of up to $79.00 per share represents a significant premium: approximately 40% to the Company's closing price on May 23, 2025 (the last full trading day prior to media reports regarding a possible transaction), and 46% to the same unaffected price when including the maximum CVR.
• A significant majority (at least 96%) of the merger consideration is upfront cash, providing certain, immediate value and liquidity to stockholders.
• The Board unanimously recommended the merger, deeming it fair and in the best interests of stockholders.
• The merger is not subject to a financing condition, with committed equity and debt financing totaling approximately $17.9 billion secured from Blackstone and TPG affiliates.
• The CVR milestones are considered 'reasonably achievable' by the Board, taking into account the business reputation and global capabilities of Blackstone and TPG.
• The go-shop period concluded without any superior acquisition proposals, suggesting the current offer is the best available.
• Early termination of the HSR Act waiting period on December 17, 2025, indicates progress on regulatory approvals.

Negatives

• The CVR portion of the consideration (up to $3.00 per share) is contingent and not guaranteed, introducing uncertainty regarding the full payout.
• A stop ship of the Brevera Breast Biopsy System Disposable 9 Gauge Needles could be prolonged, making achieving the 2026 CVR milestone more challenging.
• Stockholders will no longer participate in future earnings or growth of the Company after the merger is consummated.
• The exchange of shares for merger consideration will be a taxable transaction for U.S. federal income tax purposes, with substantial uncertainty regarding the tax treatment of CVRs.
• Restrictions on the Company's business operations are in place until the merger closes, potentially delaying or preventing certain strategic actions.
• The merger agreement contains provisions that restrict the Company's ability to solicit or engage in discussions regarding alternative takeover proposals after the go-shop period.
• A Company termination fee of $540,000,000 (or $225,000,000 during the go-shop period for an excluded party) could discourage competing bids.
• The Parent's and Merger Sub's obligations are backed by limited guarantees from the Investors, capped at $910,000,000, which is less than the total transaction value.

Risks

• The CVR milestones necessary to trigger the contingent payments may not be achieved.
• The stop ship of Brevera Breast Biopsy System Disposable 9 Gauge Needles could be prolonged, making the 2026 CVR milestone more challenging to achieve.
• Risks and costs to the Company if the merger does not close, including adverse effects on stock price, increased focus of public stockholders on short-term financial results, potential negative impact on employee retention, business disruption, and reputational harm.
• Restrictions on the conduct of the Company's business prior to the consummation of the merger may delay or prevent the Company from undertaking certain significant transactions and business opportunities.
• Regulatory agencies may delay, object to, or challenge the merger, or such approvals may not be obtained.
• The Company's obligation to pay a termination fee could discourage other potential acquirors from making an alternative proposal.
• Stockholders will not participate in any future earnings or growth (other than to the extent of any payment or payments under the CVR).
• The exchange of Company common stock for the merger consideration pursuant to the merger would be a taxable transaction for U.S. federal income tax purposes.
• Effects of the public announcement of the merger, including impacts on employees, customers, operating results, stock price, and potential for litigation.
• Parent and Merger Sub are newly formed entities with no assets, and the limited guarantees provided by funds affiliated with Blackstone and TPG guarantee obligations only up to $910,000,000.
• The financial projections in the standalone business plan are subject to certain market and sector risks not within the control of the Company, competitive dynamics, and macroeconomic risks.
• The risk that healthcare stocks would continue their historic underperformance, especially relative to technology companies.
• The Company's ability to continue to grow revenue, including identifying and executing appropriate acquisitions and attracting required talent.
• The Company's ability to sustain and expand current, sector-leading margins while accelerating growth and maintaining high product quality.
• The risk that potential future acquisitions pursued to accelerate revenue growth would not meet expectations or achieve high returns on invested capital.
• Operational risks that would negatively impact the Company's reputation with its customers.

Future Outlook

The merger is expected to be consummated in the first half of calendar year 2026, subject to stockholder approval and remaining regulatory clearances. Following the merger, Hologic, Inc. will become a wholly-owned subsidiary of Parent, and its common stock will be delisted from Nasdaq and deregistered under the Exchange Act. The Board believes the CVR milestones are 'reasonably achievable' but acknowledges that the ongoing stop ship of the Brevera Breast Biopsy System Disposable 9 Gauge Needles could make the 2026 CVR milestone more challenging to achieve.

Management Comments

• Stephen P. MacMillan (Chairman, President and CEO) stated on January 12, 2025, that the Board would consider offers to acquire the Company in line with its fiduciary duties.
• Mr. MacMillan communicated to Blackstone/TPG on June 16, 2025, that the Board found their May 11 Indication of Interest insufficient.
• Mr. MacMillan discussed with Blackstone/TPG on August 12, 2025, that some Board members expressed skepticism around the use of CVRs and the Board would want to ensure any CVR was reasonably achievable.

Industry Context

Hologic, Inc. is a global leader in women's health, focusing on diagnostics, medical imaging, and surgical products. The Board considered the rapidly evolving nature of the healthcare sector, including consolidation and increasing competitive intensity, and the historic underperformance of MedTech and Life Sciences stocks relative to technology companies. The acquisition by private equity firms Blackstone and TPG reflects a broader industry trend of private capital seeking to acquire established healthcare companies, potentially to optimize operations or pursue long-term growth strategies away from public market pressures.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for a detailed assessment against global benchmarks.
• It mentions 'trading multiples for the Company relative to its peers' but does not elaborate on specific peer comparisons or their results.

Management Changes

Corporate Governance

Legal Proceedings

• No pending lawsuits challenging the merger as of the date of the proxy statement.
• The Company has agreed to promptly notify Parent of any stockholder litigation or action against it or its representatives arising out of or relating to the merger.
• The Company will provide Parent an opportunity to review and propose comments to all filings or written responses in connection with any stockholder litigation and participate in the defense/settlement.
• The Company may not settle or agree to settle any stockholder litigation without Parent's consent.

Related Party Transactions

• No contracts or transactions or series of related contracts or transactions since September 30, 2023, that would be required to be disclosed under Item 404(a) of Regulation S-K and have not been disclosed in Company Reports.

Stakeholder Impact

• Shareholders will receive $76.00 cash per share plus a CVR for up to $3.00, representing a significant premium over the unaffected share price, but will lose direct equity ownership and voting rights in the public company. Appraisal rights are available for dissenting shareholders.
• Continuing employees will be provided with base salary/wage rates and annual target cash bonus opportunities no less favorable than prior to the merger for at least one year. Employee and fringe benefits will be substantially comparable in aggregate. Severance benefits are protected for qualifying terminations within 24 months. Retention awards have been granted to certain executive officers.
• Directors and executive officers have interests in the merger that may be different from general stockholders, including accelerated vesting of equity awards, severance payments, retention awards, and continued indemnification and insurance coverage.
• The public announcement of the merger could potentially disrupt the Company's relationships with employees, customers, suppliers, business partners, and other third parties, although the Company aims to maintain existing significant business relationships.

Next Steps

• Hold a special meeting of stockholders on February 5, 2026, to vote on the merger agreement, advisory compensation proposal, and adjournment proposal.
• Obtain remaining regulatory approvals, including CFIUS clearance and other foreign investment laws.
• Consummate the merger in the first half of calendar year 2026.
• Delist Company common stock from Nasdaq and deregister under the Exchange Act.
• Parent and the Company will cooperate to ensure CVRs are not subject to registration under securities laws.

Key Dates

Recommendation

The Board unanimously recommends the merger, which offers a substantial premium over the unaffected share price, providing immediate cash value and potential upside through the CVR. For existing shareholders, holding through the merger allows them to realize this value. The risks associated with the CVR's contingent nature and the company's standalone prospects are balanced by the certainty of the cash component and the Board's assessment of the deal's fairness, making it a reasonable path to value realization.

Keywords

Hologic, HOLX, Merger, Acquisition, Blackstone, TPG, Private Equity, Contingent Value Right, CVR, Healthcare, Medical Technology, Diagnostics, Breast Health, SEC Filing, Proxy Statement, Corporate Governance, Shareholder Vote